Long-term improvement of oxidative stress via kidney transplantation ameliorates serum sulfatide levels

Clinical and Experimental Nephrology

Volumn 16, Issue 6, 2012, Pages 959-967

  Kamijo, Yuji ^a,b   Wang, Lixuan ^b,c   Matsumoto, Akihiro ^a   Nakajima, Takero ^b   Hashimoto, Koji ^a,b   Higuchi, Makoto ^a   Kyogashima, Mamoru ^d   Aoyama, Toshifumi ^b   Hara, Atsushi ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HEBEI MEDICAL UNIVERSITY   (China)

^d NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cardiovascular disease; Kidney transplantation; Lipoprotein metabolism; Oxidative stress; Serum sulfatides

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CHOLESTEROL; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MALONALDEHYDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SULFATIDE; TACROLIMUS; URIC ACID;

ADULT; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTICLE; BRACHIAL ANKLE PULSE WAVE VELOCITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER METABOLISM; MALE; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PULSE WAVE; RISK REDUCTION; URIC ACID BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; INCIDENCE; JAPAN; KIDNEY; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SULFOGLYCOSPHINGOLIPIDS;

EID: 84876295480     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0634-2     Document Type: Article

References (30)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-69.
2. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-38.
3. Ishizuka I. Chemistry and functional distribution of sulfoglycolipids. Prog Lipid Res. 1997;36:245-319.
4. Hara A, Taketomi T. Occurrence of sulfatide as a major glycosphingolipid in WHHL rabbit serum lipoproteins. J Biochem. 1987;102:83-92.
5. 3-sulfate in serums of various mammals and its anticoagulant activity. J Biochem. 1991;110:241-5.
6. Hara A, Uemura K, Taketomi T. Sulfatide prolongs blood-coagulation time and bleeding time by forming a complex with fibrinogen. Glycoconj J. 1996;13:187-94.
7. Roberts DD, Rao CN, Magnani JL, Spitalnik SL, Liotta LA, Ginsburg V. Laminin binds specifically to sulfated glycolipids. Proc Natl Acad Sci USA. 1985;82:1306-10.
8. Roberts DD, Haverstick DM, Dixit VM, Frazier WA, Santoro SA, Ginsburg V. The platelet glycoprotein thrombospondin binds specifically to sulfated glycolipids. J Biol Chem. 1985;260:9405-11.
9. Roberts DD, Williams SB, Gralnick HR, Ginsburg V. Von Willebrand factor binds specifically to sulfated glycolipids. J Biol Chem. 1986;261:3306-9.
10. Merten M, Thiagarajan P. Role for sulfatides in platelet aggregation. Circulation. 2001;104:2955-60.
11. Kyogashima M. The role of sulfatide in thrombogenesis and haemostasis. Arch Biochem Biophys. 2004;426:157-62.
12. Hu R, Li G, Kamijo Y, Aoyama T, Nakajima T, Inoue T, et al. Serum sulfatides as a novel biomarker for cardiovascular disease in patients with end-stage renal failure. Glycoconj J. 2007;24:565-71.
13. Zhang X, Nakajima T, Kamijo Y, Li G, Hu R, Kannagi R, et al. Acute kidney injury induced by protein-overload nephropathy down-regulates gene expression of hepatic cerebroside sulfotransferase in mice, resulting in reduction of liver and serum sulfatides. Biochem Biophys Res Commun. 2009;390:1382-8.
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-92.
15. Li G, Hu R, Kamijo Y, Nakajima T, Aoyama T, Inoue T, et al. Establishment of a quantitative, qualitative, and high-throughput analysis of sulfatides from small amounts of sera by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Anal Biochem. 2007;362:1-7.
16. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem. 1998;273:5678-84.
17. Aoyama T, Uchida Y, Kelley RI, Marble M, Hofman K, Tonsgard JH, et al. A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem Biophys Res Commun. 1993;191:1369-72.
18. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem. 1989;264:10388-95.
19. Tanaka M, Ishii H, Aoyama T, Takahashi H, Toriyama T, Kasuga H, et al. Ankle brachial pressure index but not brachial-ankle pulse wave velocity is a strong predictor of systemic atherosclerotic morbidity and mortality in patients on maintenance hemodialysis. Atherosclerosis. 2011;219:643-7.
20. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399-406.
21. de Cal M, Silva S, Cruz D, Basso F, Corradi V, Lentini P, et al. Oxidative stress and "monocyte reprogramming" after kidney transplant: a longitudinal study. Blood Purif. 2008;26:105-10.
22. Campise M, Bamonti F, Novembrino C, Ippolito S, Tarantino A, Cornelli U, et al. Oxidative stress in kidney transplant patients. Transplantation. 2003;76:1474-8.
23. Minz M, Heer M, Arora S, Sharma A, Khullar M. Oxidative status in stable renal transplantation. Transplant Proc. 2006;38:2020-1.
24. Antolini F, Valente F, Ricciardi D, Fagugli RM. Normalization of oxidative stress parameters after kidney transplant is secondary to full recovery of renal function. Clin Nephrol. 2004;62:131-7.
25. Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation. 2005;79:914-9.
26. van den Dorpel MA, Ghanem H, Rischen-Vos J, Man in't Veld AJ, Jansen H, Weimar W. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int. 1997;51:1608-12.
27. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation. 1994;58:663-9.
28. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Papachristodoulou A, Kostakis AI. Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. Int Urol Nephrol. 2006;38:343-8.
29. Wanner C, Quaschning T, Weingärnter K. Impact of dyslipidemia in renal transplant recipients. Curr Opin Urol. 2000;10:77-80.
30. Osorio A, Ortega E, de Haro T, Torres JM, Sánchez P, Ruiz-Requena E. Lipid profiles and oxidative stress parameters in male and female hemodialysis patients. Mol Cell Biochem. 2011;353:59-63.